Biotronik Gets FDA Approval for Self-Expanding Stent

Biotronik has received FDA’s approval for its Pulsar-18 T3 peripheral self-expanding stent system for use in endovascular procedures.

The low-profile stent, which features a braided shaft design and thin struts, reduces vessel injury and inflammation and lowers the risk of restenosis, the company said, adding that the system may decrease the risk of access site complications and reduce the need for closure devices.

The Pulsar-18 T3 will be offered in up to a 200-millimeter stent length for the treatment of long endovascular lesions.

Biotronik will launch the new stent in the U.S. in early August.